Oxaliplatin

Two CRC cell lines (HCT116 and HT29) were bought from the Shanghai Cell Bank of the Chinese Academy of Sciences and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 100 µg/mL of penicillin- streptomycin. Oxaliplatin (Qilu Pharmaceutical Co., Ltd in Jinan, China) was dissolved in DMSO at a concentration of 30 mol/L and the cells were treated by Oxaliplatin for 24 h. CCK8 assay kit (Meilun Co.,Ltd, Nanjing, China’s) was used to detect the vitality of the cells according to the manufacturer’s instructions. Briefly, 2 × 10³ of cells were plated in 96 well plates. After treatment with DMOS or Oxaliplatin, cells were incubated in 10% CCK8 reagent for 2 h. The OD value was measured at 450 nm with TECAN Infinite 200 PRO Plate reader. Total RNA was extracted using the TRIzol chemical. The primary strand DNA was created using the PrimeScript RT chemical agent Kit and gDNA tool (Invitrogen; Thermo Fisher Scientific, Inc.). Step-by-step RT-PCR procedures were carried out in accordance with the manufacturer’s instructions. The expression of lncRNAs was measured using the 2^−ΔΔCT method. In Supplemental Tables 1, the primers for the seven lncRNAs used in the RT-PCR test are listed.

The control group was given FOLFOX4 chemotherapy regimen [12 (link)]: oxaliplatin injection (batch number HIE09099003, Qilu Pharmaceutical Co., Ltd.) 85 mg/m² was given intravenously for 2 hours on day 1, 2 h intravenous drip of leucovorin injection (batch number 1002923, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 200 mg/m², intravenous bolus injection of 5-fluorouracil (batch number 090709, Shanghai Xu Donghaipu Pharmaceutical Co., Ltd.) 400 mg/m², followed by continuous 2 h intravenous 5-fluorouracil 600 mg/m² on days 1 and 2. One course of treatment was repeated every 2 weeks, with a total of 4 courses of treatment.
The patients in the observation group were treated with modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy (same as the control group). The components of the modified Yiwei Shengyang decoction include Astragalus, Codonopsis 30 g, Poria 20 g, 15 g each of white peony root, bark lotus, Hedyotis diffusa, and Atractylodes, 10 g each of tangerine peel, Saposhnicovia divaricata, Pinellia, Alisma, and 5 g licorice, decocted with water, 1 dose/d and taken 0.5 h after breakfast and dinner. A course spans 14 days, and 3 courses of treatment were given. The patients were routinely treated with antiallergy, hydration diuresis and antiemetic symptomatic treatment according to the daily observation.

Ubenimex was purchased from Shenzhen Main Luck Pharmaceutical, Inc. (Shenzhen, China). 5-Fluorouracil and leucovorin were purchased from Xudong Haipu Pharmaceutical Co., Ltd. (Shanghai, China). Cisplatin and oxaliplatin were obtained from Qilu Pharmaceutical Co., Ltd. (Jinan, China). Rabbit anti-human CD13, Bcl-xl, Bcl-2, and Bax monoclonal antibodies were purchased from Sigma-Aldrich (St. Louis, MO). Rabbit anti-human monoclonal antibodies for XIAP, livin, and survivin were obtained from Abcam (Cambridge, UK). Rabbit anti-human antibodies for Smac, caspase-3, caspase-8, cleaved caspase-3, and cleaved caspase-8 and horseradish peroxidase (HRP)-conjugated AffiniPure goat anti-rabbit IgG (H+L) were acquired from Santa Cruz Biotechnology (Chicago, USA). Rabbit anti-human antibodies against P-gp, MRP1, ABCG2, LRP, PI3K(P85), p-PI3K(p-P85), AKT, p-AKT, GSK-3β, p-GSK-3β, JNK, p-JNK, mTOR, p-mTOR, and PE-conjugated cytochrome c (Cyto-C) mAb were obtained from Cell Signaling Technology (Danvers, MA).